Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
The FDA's recent approval of tofersen for treating SOD1-ALS marks a significant milestone, supported by compelling blood-based neurofilament light chain (NfL) measurements. This is the first instance of a blood biomarker being utilized as a surrogate endpoint for accelerated drug approval in neurology. Tofersen, which reduces the overproduction of SOD1 protein, demonstrated trends toward clinical benefit despite not significantly slowing disease progression in Phase III trials. The approach of using NfL measurements opens new avenues for neurodegenerative disease research and treatment, potentially impacting various conditions like Alzheimer's and multiple sclerosis. Quanterix Corporation, the developer of the Simoa NfL assay, plays a crucial role in this breakthrough, advancing biomarker use in clinical management.